Franco Bambi

Franco Bambi

Auto-generated profile, based on publicly available information

Franco Bambi

Cell Factory Meyer, "A. Meyer" University Children's Hospital, Florence, Italy

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2016 in Stem Cells
Verified
Journal Article
Open access
PDF file
PBPedro Barcellos-De-Souza
Pedro Barcellos-De-Souza
GCGiuseppina Comito
Giuseppina Comito
CPCoral Pons-Segura
Coral Pons-Segura
MTMaria Letizia Taddei
Maria Letizia Taddei
VGValentina Gori
Valentina Gori
PCPaola Chiarugi
Paola Chiarugi
Tumor stromal cells can supply appropriate signals that may develop aggressive phenotypes of carcinoma cells and establish a complex scenario which culminates in metastasis. Recent works proposed that bone marrow-derived mesenchymal stem cells (MSC) are recruited to primary tumors. However, the exact functions of these cells in the tumor microenvironment are not well characterized, as it is reported that MSC can either promote or inhibit tumor progression. In the present study, we aim at investigating the signaling molecules which regulate the interplay between MSC, prostate carcinoma (PCa) cells and two important cellular types constituting the tumor-associated stroma, macrophages and fibroblasts, during their progression toward malignancy. We identified TGF-β1 as a crucial molecule able to attract MSC recruitment both to PCa cells as well as to tumor stroma components. Moreover, PCa- and tumor stroma-secreted TGF-β1 is important to induce MSC transdifferentiation into carcinoma-associated fibroblast (CAF)-like cells. Consequently, the CAF-like phenotype acquired by MSC is central to promote tumor progression related effects. Thus, tumor-educated MSC enhance PCa invasiveness compared to nonactivated MSC. Additionally, differing from normal MSC, CAF-like MSC perform vascular mimicry and recruit monocytes, which can be further polarized to M2 macrophages within the PCa environment. Our findings indicate a prominent role for TGF-β1 in MSC mobilization and activation strengthened by the fact that the blockade of TGF-β1 signaling impairs MSC promotion of PCa progression. Stem Cells 2016;34:2536–2547

28 April 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
GGGiulia Grisendi
Giulia Grisendi
RBRita Bussolari
Rita Bussolari
LCLuigi Cafarelli
Luigi Cafarelli
IPIstvan Petak
Istvan Petak
VRValeria Rasini
Valeria Rasini
MDMassimo Dominici
Massimo Dominici
Adipose-derived mesenchymal stromal/stem cells (AD-MSC) may offer efficient tools for cell-based gene therapy approaches. In this study, we evaluated whether AD-MSC could deliver proapoptotic molecules for cancer treatment. Human AD-MSCs were isolated and transduced with a retroviral vector encoding full-length human tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), a proapoptotic ligand that induces apoptosis in a variety of human cancers but not normal tissues. Although several studies have documented the antitumor activity of recombinant human TRAIL, its use in vivo is limited by a short half-life in plasma due to a rapid clearance by the kidney. We found that these limitations can be overcome using stably transduced AD-MSC, which could serve as a constant source of TRAIL production. AD-MSC armed with TRAIL targeted a variety of tumor cell lines in vitro, including human cervical carcinoma, pancreatic cancer, colon cancer, and, in combination with bortezomib, TRAIL-resistant breast cancer cells. Killing activity was associated with activation of caspase-8 as expected. When injected i.v. or s.c. into mice, AD-MSC armed with TRAIL localized into tumors and mediated apoptosis without significant apparent toxicities to normal tissues. Collectively, our results provide preclinical support for a model of TRAIL-based cancer therapy relying on the use of adipose-derived mesenchymal progenitors as cellular vectors. Cancer Res; 70(9); 3718–29. ©2010 AACR.

31 October 2007 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
GAGiuseppe Astori
Giuseppe Astori
FVFrancesca Vignati
Francesca Vignati
SBSilvana Bardelli
Silvana Bardelli
MTMonica Tubio
Monica Tubio
MGMauro Gola
Mauro Gola
TMTiziano Moccetti
Tiziano Moccetti
The stromal vascular fraction (SVF) is a heterogeneous cell population derived from the adipose tissue. There is still a lack of information concerning the characterization of the cell subpopulations constituting the SVF as well as its mesenchymal and haematopoietic potential. Furthermore there are great variations in its phenotypical characterization.

13 July 2016 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
GAGiuseppe Astori
Giuseppe Astori
EAEliana Amati
Eliana Amati
FBFranco Bambi
Franco Bambi
MBMartina Bernardi
Martina Bernardi
KCKatia Chieregato
Katia Chieregato
FRFrancesco Rodeghiero
Francesco Rodeghiero
The use of fetal bovine serum (FBS) as a cell culture supplement is discouraged by regulatory authorities to limit the risk of zoonoses and xenogeneic immune reactions in the transplanted host. Additionally, FBS production came under scrutiny due to animal welfare concerns. Platelet derivatives have been proposed as FBS substitutes for the ex-vivo expansion of mesenchymal stem/stromal cells (MSCs) since platelet-derived growth factors can promote MSC ex-vivo expansion. Platelet-derived growth factors are present in platelet lysate (PL) obtained after repeated freezing–thawing cycles of the platelet-rich plasma or by applying physiological stimuli such as thrombin or CaCl2.PL-expanded MSCs have been used already in the clinic, taking advantage of their faster proliferation compared with FBS-expanded preparations. Should PL be applied to other biopharmaceutical products, its demand is likely to increase dramatically. The use of fresh platelet units for the production of PL raises concerns due to limited availability of platelet donors. Expired units might represent an alternative, but further data are needed to define safety, including pathogen reduction, and functionality of the obtained PL. In addition, relevant questions concerning the definition of PL release criteria, including concentration ranges of specific growth factors in PL batches for various clinical indications, also need to be addressed. We are still far from a common definition of PL and standardized PL manufacture due to our limited knowledge of the mechanisms that mediate PL-promoting cell growth. Here, we concisely discuss aspects of PL as MSC culture supplement as a preliminary step towards an agreed definition of the required characteristics of PL for the requirements of manufacturers and users.

1 October 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
AKAleksandra Köhler
Aleksandra Köhler
BCBowang Chen
Bowang Chen
FGFederica Gemignani
Federica Gemignani
RERosella Elisei
Rosella Elisei
CRCristina Romei
Cristina Romei
Asta FörstiAsta Försti
Asta Försti
Context: Genome-wide association studies (GWASs) of differentiated thyroid cancer (DTC) have identified associations with polymorphisms at 2q35 (DIRC3), 8p12 (NRG1), 9q22.33 (FOXE1), and 14q13.2 (NKX2-1). However, most of the inherited genetic risk factors of DTC remain to be discovered. Objective: Our objective was to identify additional common DTC susceptibility loci. Design: We conducted a GWAS in a high-incidence Italian population of 690 cases and 497 controls and followed up the most significant polymorphisms in 2 additional Italian series and in 3 low-incidence populations totaling 2958 cases and 3727 controls. Results: After excluding the most robust previously identified locus (9q22.33), the strongest association was shown by rs6759952, confirming the recently published association in DIRC3 (odds ratio [OR] = 1.21, P = 6.4 × 10−10, GWAS and all replications combined). Additionally, in the combined analysis of the Italian series, suggestive associations were attained with rs10238549 and rs7800391 in IMMP2L (OR = 1.27, P = 4.1 × 10−6; and OR = 1.25, P = 5.7 × 10−6), rs7617304 in RARRES1 (OR = 1.25, P = 4.6 × 10−5) and rs10781500 in SNAPC4/CARD9 (OR = 1.23, P = 3.5 × 10−5). Conclusions: Our findings provide additional insights into the genetic and biological basis of inherited genetic susceptibility to DTC. Additional studies are needed to determine the role of the identified polymorphisms in the development of DTC and their possible use in the clinical practice.

1 December 2013 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
PBPedro Barcellos-De-Souza
Pedro Barcellos-De-Souza
VGValentina Gori
Valentina Gori
FBFranco Bambi
Franco Bambi
PCPaola Chiarugi
Paola Chiarugi